# The Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque Psoriasis

> **NCT06833307** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Suzhou Suncadia Biopharmaceuticals Co., Ltd.** · enrollment: 90 (estimated)

## Conditions studied

- Children and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque Psoriasis

## Interventions

- **DRUG:** SHR-1314

## Key facts

- **NCT ID:** NCT06833307
- **Lead sponsor:** Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02
- **Primary completion:** 2026-07
- **Final completion:** 2026-08
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06833307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06833307, "The Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06833307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*